$CELC

Celcuity Inc. (CELC) submitted an sNDA for REVTORPYK (gedatolisib) to treat HR+/HER2- advanced breast cancer with PIK3CA mutations, based on positive Phase 3 trial data. If approved, it would be the first therapy targeting all class I PI3K isoforms and both mTOR complexes. The company projects $817.9M revenue and $267.5M earnings by 2029, up from current losses. The sNDA builds on the July 2026 approval for non-mutant cases, potentially expanding market reach.

Celcuity (CELC) submitted a supplemental New Drug Application to the FDA for REVTORPYK to treat advanced breast cancer with PIK3CA mutations. The filing is supported by Phase 3 trial results showing improved progression-free survival. If approved, REVTORPYK could become the first therapy for this indication, potentially expanding Celcuity's market. Management estimates a US$5b to US$6b addressable market and potential peak revenue of US$2.5b to US$3b for gedatolisib in this setting.

Celcuity Inc. (CELC) submitted a supplemental New Drug Application to the FDA for REVTORPYK, an investigational therapy for advanced breast cancer with a PIK3CA mutation. The application is supported by Phase 3 trial data showing significant improvements in progression-free survival and response rates. If approved, REVTORPYK would be the first therapy of its kind for this patient population. CELC stock closed at $92.27, up 1.63%.

Celcuity Inc. (CELC) reported a net loss of $78.86 million in Q2 2026, with first-half losses widening to $131.71 million. The company is advancing gedatolisib and preparing for commercialization, with FDA approval of REVTORPYK in July. Investors focus on whether REVTORPYK revenue can offset increased cash burn. Celcuity projects $817.9 million revenue and $267.5 million earnings by 2029, implying a 77% upside from current prices.

Celcuity (CELC) reported a wider net loss in Q2 2026, with a 1-month return of 13.21% and a 3-month decline of 32.34%. The company's fair value is estimated at $161.09, significantly higher than its last close at $93.53, based on growth assumptions and potential peak revenue of $2.5b to $3b for its drug gedatolisib. Future trial and regulatory decisions pose risks to this bullish outlook.

Celcuity Inc. (CELC) shares fell 26% after reporting trial results for gedatolisib in advanced breast cancer. The drug showed reduced disease progression but had treatment-related deaths. The company plans FDA filings based on these results and an upcoming decision in July.

Celcuity (CELC) reported Q2 2026 net loss of $78.9M ($1.44/ share), up from $45.3M last year. Cash reserves total $754M, with $557.2M raised from a convertible note offering. The company launched Revtopik, a drug for advanced breast cancer, and plans a supplemental New Drug Application. Clinical trials showed significant reduction in disease progression risk. Management expects cash to fund operations into 2029.

H.C. Wainwright reiterated a Buy rating and $155 price target on Celcuity (NASDAQ:CELC) after its Q2 results and corporate update. Celcuity disclosed wholesale acquisition costs of $10,000 per vial and $30,000 per cycle, targeting gross-to-net around 80%. The company said NCCN named REVTORPYK preferred Category 1 options, with payer coverage over 90% of lives. Q2 loss was $78.9M, or $1.44/share.

Celcuity (CELC) reported a wider Q2 net loss of $78.86 million and higher basic loss per share in August 2026. The company said Revtopik received FDA approval and a preferred Category 1 NCCN guideline recommendation for HR-positive, HER2-negative advanced breast cancer, which it says could affect its commercialization outlook. The article cites 2029 revenue of $817.9 million and earnings of $267.5 million.

Celcuity (NASDAQ:CELC) reported Q2 earnings call highlights for its gedatolisib programs. In REVTORPYK, adverse-event discontinuations were 5.2% (mutant cohort) for the triplet and 3.8% for the doublet, versus 19% for alpelisib. The company is expanding VIKTORIA-2 and advancing a prostate Phase Ib/II trial with darolutamide. Q2 net loss was $78.9M ($1.44/share). Cash totaled $754M.